U.S. DEPARTMENT OF HOMELAND SECURITY CERTIFIES BIOTHRAX (ANTHRAX VACCINE ADSORBED) AS AN APPROVED PRODUCT FOR HOMELAND SECURITY

Emergent BioSolutions Inc., a privately held biopharmaceutical company, announced that the United States Department of Homeland Security (DHS) has granted the company's application for designation and certification of BioThrax (Anthrax Vaccine Adsorbed) as a "qualified anti-terrorism technology" under the "Support Anti- Terrorism by Fostering Effective Technology Act" (SAFETY Act). BioThrax, the only FDA-approved vaccine for the prevention of anthrax infection, is the first vaccine to be granted such SAFETY Act coverage. Drug Newswire (http://www.drugnewswire.com/5281/)